N
DNLI icon

Natixis’s Denali Therapeutics DNLI Stock Holding History

Natixis’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-69,030
Closed -$2.12M – 1156
2022
Q3 		$2.12M Hold
69,030
– – 0.01% 594
2022
Q2 		$2.03M Sell
69,030
-167,658
-71% -$4.39M 0.01% 662
2022
Q1 		$7.61M Sell
236,688
-56,866
-19% -$1.96M 0.03% 454
2021
Q4 		$13.1M Buy
293,554
+14,300
+5% +$677K 0.04% 326
2021
Q3 		$14.1M Buy
279,254
+69,556
+33% +$3.92M 0.05% 295
2021
Q2 		$16.4M Buy
209,698
+70,000
+50% +$4.33M 0.07% 215
2021
Q1 		$7.98M Sell
139,698
-151,000
-52% -$10.1M 0.03% 417
2020
Q4 		$24.3M Buy
290,698
+264,710
+1,019% +$16M 0.09% 227
2020
Q3 		$931K Buy
+25,988
New +$783K 0.01% 535

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return